22 October 2023 at 05:48 PUBLISHED
42 batches of high blood pressure medications from five manufacturers are being recalled by the Food and Drug Administration( FDA ) due to contamination that could lead to cancer.
Acting secretary-general of the FDA Dr. Narong Aphikulvanich announced that some irbesartan models containing the azidomethyl biphenyl tetrazole ( AZBT ) impurities would be withdrawn, increasing patients’ risk of developing cancer.
But, Dr. Narong said that other irbesartan concepts that have been approved by the FDA are safe to consume.
The FDA has mandated that irbesartan producers examine these impurities, switch out AZBT-containing ingredients for non-AZB ones, and reevaluate the market’s substance supply.
Irbesartan ingredient examples were gathered by the FDA from all manufacturers, and the news came after that.
According to tests conducted by the Department of Medical Sciences, some irbesartan types contain contaminants that raise cancer risk at a level higher than international standards.
According to Dr. Narong, the FDA ordered a contraction of irbesartan from pharmacies, hospitals, and medicine manufacturers.
Patients with high blood pressure are not advised to stop taking irbesartan suddenly, according to the FDA, as hypotension necessitates regular medication use.
But, he added, patients are advised to carefully consider their medication.
The nine batches of irbesartan containing AZBT impurities are distributed by five pharmaceutical companies: Sriprasit Pharmacy Co Ltd., Government Pharmaceutical Organization, M & amp, H Manufacturing Co.